At Forte, we believe collaboration is a key driver of innovation in the clinical research industry. The upcoming 11th annual Association of American Cancer Institutes (AACI) Clinical Research Innovation (CRI) conference provides an excellent backdrop for some of the most significant collaboration among cancer center leadership in the U.S.
Representatives from nearly all NCI-designated cancer centers will attend, with the goal of developing Strategies to Maximize Innovation and Advance Cancer Clinical Research. As a sponsor of the conference, the Forte team will be on hand to stay on top of industry trends and connect with customers using our OnCore Enterprise Research System, Forte eRegulatory Management System and Forte Research Evaluation System.
If you plan on attending the conference, we hope you can stop by our booth to connect. If not, here are a few recent Forte educational resources that touch on some of the conference focus areas.
Improving Efficiency and Expertise Among Research Staff
Clinical research professionals are increasingly faced with a wide array of new technologies in their day-to-day work. As research outcomes become more dependent on these technologies, the need for adoption, training and support grows exponentially. Forte partnered with ACRP to evaluate the current state of technology expertise and adoption throughout the industry.
You can view the results of the Forte/ACRP survey, and also watch an on-demand webinar with Forte’s Wendy Tate and ACRP’s Workforce Innovation Officer Beth Harper, where they discuss the results and what it means for the future of the industry.
Effectively Running Multi-Site Trials
For large academic research sites, managing multi-site trials can be a significant challenge. Much of the burden can be eased by technology—an enterprise-level clinical trial management system (CTMS) can provide the tools you need to manage studies from protocol set-up and activation through close-out, subject screening and registration, reporting and analytics and more.
From a regulatory perspective, using mail, email and antiquated file share systems to manage essential protocol documents across multiple sites can strain resources and potentially create issues with compliance. We recently collaborated with customers to develop the industry’s first eReg system capable of managing complex multi-center trials. You can read about our approach and our progress here:
Study Pre-Activation: Improving Feasibility
Feasibility determinations are a vital step in study pre-activation, but many sites struggle with both the timing and efficiency of the process. As studies become more complex and patient recruitment becomes more challenging, the clinical research industry needs to rethink existing feasibility processes.
At the AACI-CRI conference, presenters from the Stephenson Cancer Center at the University of Oklahoma and Memorial Sloan Kettering Cancer Center will discuss their processes for dealing with the study pre-activation challenge. You can also find more information by reading our article How Clinical Research Sites Can Improve the Feasibility Process, and learn more about improving site/sponsor relationships (including the feasibility process) in our eBook, Improving Site-Sponsor Relationships: Proactive Strategies for Transparent Clinical Trials.
Recruiting a Diverse Population to Your Studies
For NCI-designated cancer centers, enrolling patients from diverse backgrounds is key to achieving positive outcomes and to meeting the requirements needed to maintain the Cancer Center Support Grant (CCSG). The FDA has also promoted patient diversity across all clinical trials (including non-oncology) with respect to race, age, gender and more.
You can learn more about diversity and inclusion in our article Diverse Populations, Inclusive Practices: Why Diversity in Clinical Research Matters.
To learn more about these and other hot topics within the clinical research industry, check out our Educational Clinical Research Resources.